Intrinsiqq
Neumora Therapeutics, Inc. logo

Neumora Therapeutics, Inc. Insider Trading

NMRA

Compare
Last 12 months

Insiders sold 784K and bought nothing on the open market.

1% of the selling was scheduled in advance under 10b5-1 plans. See Remarks Daljit Singh Aurora sold 432K on Aug 19, 79% of their stake, outside a plan. The last open-market buy by an executive or director was in Oct 2025.

Net open-market
−784K
0 buys · 6 sales
Under a 10b5-1 plan
1%
of the value sold
Insiders who bought / sold
0 / 4
executives and directors
Last open-market buy
Oct 2025
Oct 27, 2025

Get an email when NMRA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Aug 20 – 21No plan
    Daljit Singh Aurora
    See Remarks · sold 176,060 at avg $1.53
    269K
    78% of stake
  • Aug 17 – 19No plan
    Daljit Singh Aurora
    See Remarks · sold 277,773 at avg $1.56
    432K
    79% of stake
  • Feb 17No plan
    Daljit Singh Aurora
    See Remarks · sold 6,165 at $3.56
    22K
    6.9% of stake
  • Feb 17No plan
    Joshua Pinto
    President · sold 5,967 at $3.54
    21K
    2.8% of stake
  • Feb 17No plan
    Paul L Berns
    See Remarks · sold 9,819 at $3.51
    34K
    0.1% of stake
  • Feb 1710b5-1 plan
    Michael Lee Milligan
    See Remarks · sold 1,436 at $3.57
    5K
    6.4% of stake
  • Nov 11, 202510b5-1 plan
    Daljit Singh Aurora
    See Remarks · sold 114,703 at $2.68
    307K
    56% of stake
  • Oct 27, 2025
    Kristina Burow
    Director · bought 1,915,700 at $2.61
    $5M
    6.0% of stake
  • Oct 27, 2025
    Arch Venture Partners Xii, LLC
    Large holder · bought 1,915,700 at $2.61
    $5M
    6.0% of stake
  • Oct 27, 2025
    Arch Venture Partners Viii, LLC
    Large holder · bought 1,915,700 at $2.61
    $5M
    6.0% of stake
  • Feb 18, 202510b5-1 plan
    Paul L Berns
    See Remarks · sold 13,871 at $1.69
    23K
    0.2% of stake
  • Feb 18, 202510b5-1 plan
    Michael Lee Milligan
    See Remarks · sold 1,978 at $1.69
    3K
    8.1% of stake
  • Feb 18, 202510b5-1 plan
    Daljit Singh Aurora
    Chief Strategy Officer · sold 8,565 at $1.68
    14K
    4.0% of stake
  • Feb 18, 202510b5-1 plan
    Robert A. Lenz
    Head of R&D · sold 5,614 at $1.67
    9K
    1.8% of stake
  • Feb 18, 202510b5-1 plan
    Joshua Pinto
    President · sold 8,048 at $1.67
    13K
    3.6% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch NMRA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with NMRA

CompareIntrinsic value
TILInstil Bio, Inc.
$5.23-5.77%10
IVVDInvivyd Inc.
$0.41-7.47%10
LXEOLexeo Therapeutics Inc.
$2.96+0.34%10
ELOXEloxx Pharmaceuticals, Inc.
$10.75+0.94%20
CLDICalidi Biotherapeutics Inc.
$0.48-5.45%19
INBXInhibrx Biosciences, Inc.
$68.97-7.21%18
CRISCuris Inc.
$0.44-7.21%35
DYAIDyadic International Inc.
$0.29-6.45%25

Held by ETFs

NMRA is in 5 US ETFs. The largest of them, with NMRA's weight in each:

Spot a number that looks wrong? Check it in NMRA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing NMRA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.